{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:21:32Z","timestamp":1789042892456,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-58952-7","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T12:26:03Z","timestamp":1781958363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical benefit of palbociclib retreatment after abemaciclib exposure in hormone receptor positive, HER2 negative metastatic breast cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Muhan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takabatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junta","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Teranaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"58952_CR1","unstructured":"Howlader N, N.A., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Cancer statistics review, 1975\u20132018. 2021."},{"issue":"19","key":"58952_CR2","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan, H. et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19), 1836\u20131846 (2017).","journal-title":"N Engl J Med"},{"key":"58952_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/CMAR.S72592","volume":"7","author":"WA Harb","year":"2015","unstructured":"Harb, W. A. Management of patients with hormone receptor-positive breast cancer with visceral disease: Challenges and treatment options. Cancer Manag Res 7, 37\u201346 (2015).","journal-title":"Cancer Manag Res"},{"issue":"2","key":"58952_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","volume":"21","author":"JJ Gao","year":"2020","unstructured":"Gao, J. J. et al. CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: A US food and drug administration pooled analysis. Lancet Oncol 21(2), 250\u2013260 (2020).","journal-title":"Lancet Oncol"},{"issue":"7","key":"58952_CR5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/cncr.34675","volume":"129","author":"RK Goyal","year":"2023","unstructured":"Goyal, R. K. et al. Overall survival associated with CDK4\/6 inhibitors in patients with HR+\/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer 129(7), 1051\u20131063 (2023).","journal-title":"Cancer"},{"issue":"4","key":"58952_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im, S. A. et al. Overall Survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 381(4), 307\u2013316 (2019).","journal-title":"N Engl J Med"},{"issue":"1","key":"58952_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge, G. W. Jr. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. JAMA Oncol 6(1), 116\u2013124 (2020).","journal-title":"JAMA Oncol"},{"issue":"12","key":"58952_CR8","first-page":"2821","volume":"9","author":"B Rozeboom","year":"2019","unstructured":"Rozeboom, B., Dey, N. & De, P. ER+ metastatic breast cancer: Past, present, and a prescription for an apoptosis-targeted future. Am J Cancer Res 9(12), 2821\u20132831 (2019).","journal-title":"Am J Cancer Res"},{"issue":"3","key":"58952_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","volume":"34","author":"P Razavi","year":"2018","unstructured":"Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34(3), 427\u2013438 (2018).","journal-title":"Cancer Cell"},{"issue":"2","key":"58952_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10549-024-07469-6","volume":"208","author":"A Brufsky","year":"2024","unstructured":"Brufsky, A. et al. Trends in HR+ metastatic breast cancer survival before and after CDK4\/6 inhibitor introduction in the United States: A SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer. Breast Cancer Res Treat 208(2), 223\u2013235 (2024).","journal-title":"Breast Cancer Res Treat"},{"key":"58952_CR11","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Breast cancer 2022. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"issue":"12","key":"58952_CR12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari, A. et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12), 1475\u20131495 (2021).","journal-title":"Ann Oncol"},{"key":"58952_CR13","unstructured":"Japanese Breast Cancer Society (JBCS) Guidelines."},{"issue":"1","key":"58952_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41523-023-00578-3","volume":"9","author":"J Ma","year":"2023","unstructured":"Ma, J. et al. Emerging systemic therapy options beyond CDK4\/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer 9(1), 74 (2023).","journal-title":"NPJ Breast Cancer"},{"issue":"34","key":"58952_CR15","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston, S. R. D. et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38(34), 3987\u20133998 (2020).","journal-title":"J Clin Oncol"},{"key":"58952_CR16","doi-asserted-by":"publisher","first-page":"GS3","DOI":"10.1158\/1538-7445.SABCS22-GS3-06","volume":"83","author":"EL Mayer","year":"2023","unstructured":"Mayer, E. L. et al. Abstract GS3\u201306: GS3\u201306 palbociclib after CDK4\/64i and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+\/HER2- metastatic breast cancer. Cancer Res. 83, GS3-GS06 (2023).","journal-title":"Cancer Res."},{"key":"58952_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1200\/JCO.2023.41.16_suppl.1001","volume":"41","author":"CH-W Antonio Llombart-Cussac","year":"2023","unstructured":"Antonio Llombart-Cussac, C.H.-W. et al. Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])\/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. J Clin Oncol. 41, 1001\u20131001 (2023).","journal-title":"J Clin Oncol."},{"issue":"24","key":"58952_CR18","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky, K. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol 41(24), 4004\u20134013 (2023).","journal-title":"J Clin Oncol"},{"issue":"9","key":"58952_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky, K. et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: Results from the phase III postMONARCH trial. J Clin Oncol 43(9), 1101\u20131112 (2025).","journal-title":"J Clin Oncol"},{"key":"58952_CR20","doi-asserted-by":"publisher","first-page":"S409","DOI":"10.1016\/j.annonc.2025.08.922","volume":"36","author":"M Nishimura","year":"2025","unstructured":"Nishimura, M. et al. 499P Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive and HER2-negative metastatic breast cancer: Results from the phase & #x2161; AGAIN study (WJOG14220B). Ann. Oncol. 36, S409 (2025).","journal-title":"Ann. Oncol."},{"issue":"8","key":"58952_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","volume":"26","author":"M Hafner","year":"2019","unstructured":"Hafner, M. et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity. Cell Chem Biol 26(8), 1067\u20131080 (2019).","journal-title":"Cell Chem Biol"},{"issue":"5","key":"58952_CR22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"Gelbert, L. M. et al. Preclinical characterization of the CDK4\/6 inhibitor LY2835219: In-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Invest New Drugs 32(5), 825\u2013837 (2014).","journal-title":"Invest New Drugs"},{"issue":"25","key":"58952_CR23","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge, G. W. Jr. et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35(25), 2875\u20132884 (2017).","journal-title":"J Clin Oncol"},{"issue":"32","key":"58952_CR24","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz, M. P. et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32), 3638\u20133646 (2017).","journal-title":"J Clin Oncol"},{"issue":"20","key":"58952_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20), 1925\u20131936 (2016).","journal-title":"N Engl J Med"},{"issue":"3","key":"58952_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.21.02554","volume":"40","author":"M Gnant","year":"2022","unstructured":"Gnant, M. et al. Adjuvant palbociclib for early breast cancer: The PALLAS trial results (ABCSG-42\/AFT-05\/BIG-14-03). J Clin Oncol 40(3), 282\u2013293 (2022).","journal-title":"J Clin Oncol"},{"issue":"14","key":"58952_CR27","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1200\/JCO.20.03639","volume":"39","author":"S Loibl","year":"2021","unstructured":"Loibl, S. et al. Palbociclib for residual high-risk invasive hr-positive and her2-negative early breast cancer:The penelope-B trial. J Clin Oncol 39(14), 1518\u20131530 (2021).","journal-title":"J Clin Oncol"},{"issue":"18","key":"58952_CR28","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1200\/JCO-24-01865","volume":"43","author":"A Llombart-Cussac","year":"2025","unstructured":"Llombart-Cussac, A. et al. Second-line endocrine therapy with or without palbociclib rechallenge in patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: PALMIRA trial. J Clin Oncol 43(18), 2084\u20132093 (2025).","journal-title":"J Clin Oncol"},{"issue":"6","key":"58952_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6), 520\u2013529 (2012).","journal-title":"N Engl J Med"},{"issue":"1","key":"58952_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13058-021-01394-y","volume":"23","author":"M Rozenblit","year":"2021","unstructured":"Rozenblit, M. et al. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Breast Cancer Res 23(1), 14 (2021).","journal-title":"Breast Cancer Res"},{"issue":"14","key":"58952_CR31","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner, N. C. et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol 37(14), 1169\u20131178 (2019).","journal-title":"J Clin Oncol"},{"issue":"7","key":"58952_CR32","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1535-7163.MCT-11-0963","volume":"11","author":"CE Caldon","year":"2012","unstructured":"Caldon, C. E. et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 11(7), 1488\u20131499 (2012).","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"58952_CR33","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu, M. T. et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76(8), 2301\u20132313 (2016).","journal-title":"Cancer Res"},{"issue":"8","key":"58952_CR34","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander, S. A. et al. The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer. Cancer Discov 10(8), 1174\u20131193 (2020).","journal-title":"Cancer Discov"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58952-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58952-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58952-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:02:29Z","timestamp":1789041749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58952-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58952"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58952-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board of Chiba University Hospital approved this study on February 24, 2023 (Approval No. HK202302-04). As Shikoku Cancer Center participated under the centralized ethical approval obtained by Chiba University Hospital, the same approval number was applied at both institutions. The study was not associated with a clinical trial in Japan. This study complied with all relevant ethical regulations regarding patient data and was conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the Institutional Review Board of Chiba University Hospital because of the retrospective nature of the study and the use of anonymized data. An opt-out method was used to allow patients to refuse participation.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study used anonymized data and does not include any identifiable individual information.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28313"}}